<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/189A3955-400D-4828-AB31-171231353C76"><gtr:id>189A3955-400D-4828-AB31-171231353C76</gtr:id><gtr:name>Nova Biopharma Technologies Ltd</gtr:name><gtr:address><gtr:line1>Martin House
Gloucester Crescent</gtr:line1><gtr:city>Wigston</gtr:city><gtr:postCode>LE18 4YF</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/189A3955-400D-4828-AB31-171231353C76" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>189A3955-400D-4828-AB31-171231353C76</gtr:id><gtr:name>Nova Biopharma Technologies Ltd</gtr:name><gtr:address><gtr:line1>Martin House
Gloucester Crescent</gtr:line1><gtr:city>Wigston</gtr:city><gtr:postCode>LE18 4YF</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>428646.0</gtr:offerGrant><gtr:projectCost>428646.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1389C81F-AEF9-49BB-B87B-C58094D58CAD"><gtr:id>1389C81F-AEF9-49BB-B87B-C58094D58CAD</gtr:id><gtr:firstName>Sam</gtr:firstName><gtr:surname>de Costa</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=972225"><gtr:id>701C7D22-D921-4B2C-B73E-A44BC80B42D4</gtr:id><gtr:title>Room temperature stable MVA-GP pox vectored vaccine against CCHF</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Small Business Research Initiative</gtr:grantCategory><gtr:grantReference>972225</gtr:grantReference><gtr:abstractText>The objective of the proposed programme is to achieve a room-temperature stable, ready-to-inject vaccine against Crimean-Congo haemorrhagic fever (CCHF). HydRIS (Hypodermic Re-hydration Injection System) stabilisation platform with a proven track record of successfully stabilising live viral and bacterial vectors will be assessed to stabilise MVA-GP vaccine- a novel pox-vector based vaccine against CCHF developed by the Health Protection Agency. The successful completion of the programme will enable to develop a CCHF vaccine that will not rely on the cold-chain-distribution, which is especially challenging in certain parts of the world vulnerable to CCHF. As a platform technology, this programme will further demonstrate the applicability to a range of MVA-vectored vaccines. Nova Biopharma Technologies part of Nova Group continue to develop cutting edge technologies supported by it's advanced manufacturing capabilities for both clinical and commercial manufacturing scales. PHE exists to protect and improve the nation?s health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. PHE Porton undertakes basic and applied research into understanding infectious diseases, with expertise in high containment pathogens. PHE Porton specialise in translational research to develop and test interventions for public health, including new products such as vaccines and diagnostics.</gtr:abstractText><gtr:fund><gtr:end>2017-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>428646</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">972225</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>